Hyphema Post Intravitreal Injection of Bevacizumab
Lucrèce Joanelle Vydalie Eriga *
Department of Ophthalmology, Hôpital Militaire D’instruction Mohammed V, Rabat, Morocco.
Arnaud Hugues Yempabou Yonli
Department of Ophthalmology, Hôpital Militaire D’instruction Mohammed V, Rabat, Morocco.
Ricardo Mendes
Department of Ophthalmology, Hôpital Militaire D’instruction Mohammed V, Rabat, Morocco.
Yassine Mouzari
Department of Ophthalmology, Hôpital Militaire D’instruction Mohammed V, Rabat, Morocco.
Abdelbarre Oubaaz
Department of Ophthalmology, Hôpital Militaire D’instruction Mohammed V, Rabat, Morocco.
*Author to whom correspondence should be addressed.
Abstract
Objective: To describe a case of total hyphema after intravitreal injection of Bevacizumab.
Results: This is a 54 years old patient diagnosed with exudative age-related macular degeneration who was admitted for injection of Bevacizumab in the right eye. The visual acuity was 02/10 in both eyes, and the injection was performed after eliminating the contraindications on biomicroscope examination. The immediate evolution after injection was marked by a total hyphema. The management was based on antibiotic and anti-inflammatory eye drops, rehydration and monitoring. The hyphema disappeared after ten days with visual acuity remained at 02/10.
Keywords: Hyphema, bevacizumab, exudative, macular
How to Cite
Downloads
References
TIEN LEV. Epidémiologie de la DMLA. Realites Ophtalmologiques. Mai. 2013;203:12-14.
Tick S, Cornut PL, Bats De F, Wolf B, Souied EH, Cohen SY. Actualisations de la federation france macula : Prise en charge therapeutique de la dmla exsudative. Journal Français d'Ophtalmologie. 2018; 41(9):862-867.
MS Ip, Scott IU, Brown GC, et al. Anti-vascular endothelial growth factor pharmacotherapy for age-related macular degeneration: A report by the American academy of ophthalmology. Ophthalmology. 2008;115:1837.
Kaya M, Öner FH, Akbulut Yağcı B, Ataş F, Öztürk T. Non-infectious intraocular infammation following intravitreal anti-vascular endothelial growth factor injection. Turk J Ophthalmol. 2021;51(1):32–7 Available:https://doi.org/10.4274/tjo.galenos.2020.84042
Fung AE, Rosenfeld PJ, Reichel E. The International Intravitreal Bevacizumab Safety Survey: Using the internet to assess drug safety worldwide. Br J Ophtalmol. 2006;90:1344–1349.
Korobelnik JF, Cochereau I, Cohen SY, Coscas G, Creuzot-Garcher C, Devin F, Weber M. Description des pratiques pour la réalisation des injections intravitréennes. Journal français d'ophtalmologie. 2006; 29(1):82-86.
Tushar M Ranchod, Mark K Walsh, Antonio Capone Jr, Tarek S Hassan, George A Williams. Hyphema after intravitreal injection of ranibizumab or bevacizumab; 2011.
Klein R, Klein BE, Lee KE, Cruickshank’s KJ, Gagnon RE. Changes in visual acuity in a population over a 15-year period: The Beaver Dam Eye Study. Am J Ophtalmol. 2006;142:539–549.
Cohen SY, Girmens JF. DMLA: les traitements à venir [AMD: Future therapies]. J Fr Ophtalmol. 2011;34(7):498-501. French. DOI: 10.1016/j.jfo.2011.04.004. Epub 2011 Jun 11. PMID: 21658792
Merle B. Epidémiologie nutritionnelle et vieillissement oculaire : le cas de la dégénérescence maculaire liée à l’âge (DMLA). Cahiers de Nutrition et de Diététique ; 2023.
Miller A, Wilneff MA, Yazji A, Petrinec E, Carbone M, Miller C, McCrossin C, Donkor R, Miller DG. Analysis of urgent follow up visits and complications after intravitreal injections: A retrospective cohort study. Int J Retina Vitreous. 2022;8(1);8. DOI: 10.1186/s40942-021-00358-w. PMID: 35042547; PMCID: PMC8764861
Ramos MS, Xu LT, Singuri S, et al. Patient-reported complications after intravitreal injection and their predictive factors. Ophthalmol Retina. 2021;5(7):625–32 Available:https://doi.org/10.1016/j.oret.2020.09.024
Xu K, Chin EK, Bennett SR, et al. Endophthalmitis after intravitreal injection of vascular endothelial growth factor inhibitors: Management and visual outcomes. Ophthalmology. 2018;125: 1279e1286.
Tufan HA, Vural A, Gencer B, Kara S, Arikan S, Yuksel E. Contamination bactérienne des aiguilles utilisées pour les injections intravitréennes : Comparaison entre les aiguilles de calibre 27 et celles de calibre 30. Ocul Immunol Inflamm. 2013; 21:366-370.
Grzybowski A, Told R, Sacu S, Bandello F, Moisseiev E, Loewenstein A, Schmidt-Erfurth U. Update on Intravitreal Injections: Euretina Expert Consensus Recommendations. Ophthalmologica. 2018;239:181–93. Available:https://doi.org/10.1159/000486145
Wong LJ, Desai RU, Jain A, et al. Surveillance for potential adverse events associated with the use of intravitreal bevacizumab for retinal and choroidal vascular disease. Retina. 2008;28:1151–1158.